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Summary
This paper applies the inverse probability weighted (IPW) least-squares method to estimate the eﬀects of treatment
on total medical cost, subject to censoring, in a panel-data setting. IPW pooled ordinary-least squares (POLS) and
IPW random eﬀects (RE) models are used. Because total medical cost might not be independent of survival time
under administrative censoring, unweighted POLS and RE cannot be used with censored data, to assess the eﬀects of
certain explanatory variables. Even under the violation of this independency, IPW estimation gives consistent
asymptotic normal coeﬃcients with easily computable standard errors. A traditional and robust form of the
Hausman test can be used to compare weighted and unweighted least squares estimators. The methods are applied to
a sample of 201 Medicare beneﬁciaries diagnosed with lung cancer between 1994 and 1997. Copyright # 2006 John
Wiley & Sons, Ltd.
JEL classiﬁcation: C23; I1
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Introduction
Rising health care expenditures in many industrialized countries has spurred the development of
methods for analysis of medical costs in conjunction with evaluation of health outcomes. Challenges in analyzing cost data include addressing
skewness in cost distributions, heterogeneity
across samples and more challenging, complexities
due to censoring.
Ordinary least squares estimation (OLS) can be
used to analyze cost data under exogenous
censoring. With exogenous censoring, once covariates have been selected, the total cost Y over the
period T (survival time) are assumed independent.

With longitudinal data, administrative censoring is
due to study termination when, for instance, the
analyst chooses a closing date for data collection.
In these circumstances, OLS is not appropriate
because total costs and survival time are likely to
be associated. Because longer survival times and
their associated costs are more likely to be
censored, estimates of cost based only on the
uncensored cases are biased towards patients with
shorter survival times.
In this paper, we apply an inverse probability
weighted (IPW) least squares method to assess the
eﬀects of covariates (e.g. patient and clinical
characteristics) on medical cost with censored
data. In our application to costs in patients
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diagnosed with lung cancer, we aim to observe the
eﬀects of treatment on average cost per subperiod
(e.g. monthly, quarterly) over a circumscribed
window of observation. In particular, our method
examines how various treatment regimens (e.g.
surgery only, chemotherapy, radiation and combinations of surgery, chemotherapy, and radiation)
aﬀects the cost of lung cancer care per month over
the two years of initial diagnosis.
The IPW least squares method has a long
history in statistics [1–6]. Our work is strongly
inﬂuenced by the more general framework that
develops the asymptotic properties of the IPW
M-estimator for variable probability samples [7, 8].
IPW least squares produces consistent asymptotically normal coeﬃcients with easily computable
standard errors, even under violation of the
exogenous censoring assumption.
Other published applications of IPW estimation
included Lin [9, 10] Jain and Strawderman [11] and
Willan et al. [12]. Lin [9, 10] developed a method to
estimate the mean cost conditional on covariates
from data subject to censoring. Jain and Strawderman [11] extend Lin’s method to implement
inverse probability of censoring weighted estimation in a hazard regression model for the conditional distribution of life time cost given
covariates. Both of these methods analyze the
cross-sectional data. Willan et al. [12] proposed an
extension of Lin’s methods to allow for longitudinal structure for cost eﬀectiveness analysis. In
particular, the researchers use seemingly unrelated
regression (SUR) equations when comparing two
groups in a cost eﬀectiveness analysis. In contrast,
our model controls for both continuous and
several categorical time dependent variables,
whereas Willan et al. [12] have only one categorical
time dependent variable.
Another popular approach in the health services
literature is to create a measure of cost perindividual per-month from longitudinal data on
expenditures over the period of cost accumulation.
Our proposed method is based on panel data.
Thus, it diﬀers from that of Lin [9,10] and Jain and
Strawderman [11]. Using data gathered over time
from the same cross sectional units is useful for
several reasons. First, it allows us to examine
dynamic relationships, which is not possible with a
single cross section. Second, the panel data
structure extends Lin’s method to accommodate
covariates that are time dependent.
The panel data model is conceptually diﬀerent
from the SUR model. The errors, for example, are
Copyright # 2006 John Wiley & Sons, Ltd.
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homoskedastic and serially independent both
within and between individuals. In SUR models
the errors are allowed to be contemporarily
correlated and heteroskedastic between individuals. If there are a large number of independent
individuals observed (more than 500) for a few
time periods (less than 30), it is not possible to
estimate diﬀerent individual slopes for all the
exogeneous variables. Panel data are not subject to
these restrictions.
None of the previous work using IPW methods
oﬀers a test to compare their methodology with
potential bias methods. As a secondary contribution, we show how to apply a traditional and
robust form of the Hausman test [13] to determine
if systematic diﬀerences are present between OLS
and IPW least squares methods. This allows us to
determine whether bias introduced by applying
OLS on the uncensored data leads to statistically
signiﬁcant diﬀerences in the coeﬃcients.
We ﬁrst introduce IPW pooled ordinary least
squares (POLS) and IPW random eﬀects (RE)
models. The choice between the two models is
dependent upon the presence of unobserved
heterogeneity in the data. The next section
describes the proposed Hausman type of test. We
demonstrate our methods for assessing covariate
eﬀects on costs using data from Medicare claim
ﬁles for a sample of patients diagnosed with lung
cancer. Further, we present the detail of application. The ﬁnal section summarizes our ﬁndings. All
technical details are presented in Appendix A.

General framework
Suppose that we are interested in the total medical
cost over period ½0; L. If there are data on cost and
explanatory variables at multiple intervals such as
months or years, they ﬁt naturally into a panel
format. Let the entire time period of interest be
divided into G intervals: 0 ¼ t0 5t1 5    5tG ¼ L.
Since there is no further medical expense after
death, the total cost over ðtg1 ; tg  is the same as
the cost incurred up to Tgn ¼ minðT; tg Þ, where T is
the survival time. The distribution of T is assumed
to be continuous from 0 to L.
Survival time and medical cost may be subject to
right censoring and therefore are not always fully
observable. Censoring of cost occurs when a
patient’s follow-up time is less than tG , and the
patient is alive at the time of censoring. Because no
Health Econ. 15: 513–525 (2006)
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further expense is incurred after death, for all
observed deaths the total costs are known.
One advantage of dividing the total period into
intervals is that we can consider the ith individual
as uncensored in the gth interval ðtg1 ; tg  whenever
the censoring time C exceeds the minimum of T
and tg . Therefore, some individuals regarded as
censored in studies which we do not partition the
period of interest can be considered uncensored in
some intervals during the period of interest.
For the ith individual let Tin ¼ minðTi ; LÞ, Zi ¼
minðTin ; Ci Þ and sig ¼ IðCi  Tign Þ, where Ið:Þ is the
indicator function. Therefore, cost in the gth
interval is censored if sig ¼ 0.
Let yig be the medical cost (or log-transformed
cost) for the ith individual in the interval ðtg1 ; tg .
If there is an initial cost at t ¼ 0, we include that
cost in ﬁrst time interval. The following situations
arise:

usual linear model for independent identically
distributed cross-sections: for each i

(a) Zi  tg : Here the patient survives beyond tg
and is not censored by time tg . Therefore yig is
observed.
(b) Zi  tg1 and sig ¼ 1: If death occurs in
ðtg1 ; tg  then Ti is observed. The period costs
yig in ðtg1 ; T is observed. If death does not
occur in ðtg1 ; tg  then we are back to (a).
(c) Zi  tg1 and sig =0: Here censoring occurs in
ðtg1 ; tg  and the cost yig is censored.
(d) Zi 5tg1 : Either death or censoring precedes
tg1 . Therefore, the cost yig in ðtg1 ; tg  is either
zero (if death had occurred) or is censored.

Under assumption 1, the unweighted POLS
estimator b#up of b
!1
!
N
N
X
X
1
0
#bup ¼ N 1
*X0 X
*i
*
Xi y* i
N
i

(a)–(d) captures all possibilities. For example, if
our study is 12 months and costs are assessed
monthly, then an observed death in month 1
would mean that yit ð 0Þ is observed, and yi2 ¼
   ¼ yi12 ¼ 0 for the next 11 months. According
to our model we will use all the yig ’s as long as
sig ¼ 1. This is true for the POLS estimator b#up and
IPW POLS estimator b#wp that we describe next.
The asymptotic theory of the estimators b#up and
b#wp still hold true, although one could claim that
we could do better modelling the zero-cost
observations. We will mention this again after
introducing our random eﬀects model.

yi ¼ Xi b þ ui

i ¼ 1; 2; . . . ; N

ðx0i1 ; x0i2 ; . . . ; x0iG Þ0

where Xi ¼
is G  K matrix of
explanatory variables, b is the K  1 vector of
unknown regressions parameters, ui is G  1
vector of unobservables whose distribution is
unspeciﬁed. Let Si be a G  G matrix whose gth
diagonal element sig ¼ 1 if ðxig ; yig Þ is observed,
zero otherwise. Generally, we have an unbalanced
panel. We can deﬁne our explanatory variables
and response variables for the selected sample as
* i ¼ Si Xi , *yi ¼ Si yi .
X
Assumption 1.
(i) Eðui jXi Þ ¼ 0;
(ii) Eðui jXi Þ ¼ Eðui jXi ; Si Þ;
*
* 0X
(iii) EðX
i i Þ has rank K.

i¼1

i¼1

is consistent, asymptotically normal with its
asymptotic robust variance matrix estimated by
# 1 B
# # 1
# up ¼ A
V
up up Aup =N
where
# up ¼ N 1
A

N
X

* 0X
*
X
i i

!

i¼1

# up ¼ N 1
B

N
X
i¼1

* 0 ðu* i Þðu* i Þ0 X
*i
X
i
% %

* i b#up .
and *ui ¼ *yi  X
%
Assumption
1(ii) is the key exogenous censoring
assumption underlying the validity of the
unweighted POLS estimator from the censored
sample. This assumption is not true in the
estimation of medical cost from administratively
censored data, because assumption 1(ii) entails,
for all g
Eðyig jxig ; sig Þ ¼ Eðyig jxig Þ

Pooled ordinary least squares estimation
(POLS)
The properties of POLS under exogenous censoring can be summarized as follows. Assume the
Copyright # 2006 John Wiley & Sons, Ltd.

ð1Þ

Under administrative censoring, although Ci and
yig are independent, yig and Ti could be correlated.
We will see that IPW least squares estimation
produces a consistent, asymptotically normal
estimator of b even when (1) does not hold, but
Health Econ. 15: 513–525 (2006)
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under the following assumptions. Suppose that T
and C are independent given x.
Assumption 10 .
(i) EðX0i ui Þ ¼ 0;
*
* 0X
(ii) EðX
i i Þ has rank K;
(iii) xig and yig are ignorable in the censoring
equation, that is

# wp ¼ N 1
B

N
X

# 0 ð#ui Þð#ui Þ0 X
#i
X
i

i¼1

Pðsig ¼ 1jxig ; yig ; Ti Þ
A

¼ PðCi  Tign jxig ; yig ; Ti Þ
B

¼ PðCi  minðtig ; LÞjxig ; yig ; Ti Þ
C

¼ Pðsig ¼ 1jTi Þ
A is the deﬁnition of sig ¼ 1; B is the deﬁnition of
Tign ; C is a consequence of the assumption that the
censoring time Ci is independent of ðxig ; yig ; Ti Þ and
L is constant. For similar formats see for example
Lin [9]. We observe Ti whenever Ti is uncensored,
we observe Ci when si ¼ 0. A weaker assumption
would be that the censoring time Ci is independent
of ðyig ; Ti Þ given xig . The censoring probability is
then Pðsig ¼ 1jxig ; yig ; Ti Þ ¼ Pðsig ¼ 1jTi Þ.
Another advantage of weighting the observations, other than solving the censoring problem,
is that we derive consistency with the weaker
assumption 10 (i) rather than assumption 1(i).
Assumption 10 (ii) is the appropriate rank condition. Assumption 10 (iii) requires that the censoring
probability is observable when sig ¼ 1.
Under Assumption 10 the IPW POLS estimator
is, b#wp
!
N
X
1
1
0
#
# y# i
N
X
b# wp ¼ A
wp

where

i

# i b#wp .
and u# i ¼ y# i  X
Each observation of ðyi ; xi Þ is weighted by the
inverse probability of appearing in the sample.
Assumption 10 (iii) requires the function pðtÞ to be
known, so b#wp is computable from observed data.
The estimated covariance matrix in (3) is the
White heteroskedasticity-robust covariance matrix
[14] applied to all variables for observation i in the
gth interval and weighted by the inverse probability of appearing in the sample. Hence, under
our assumptions censoring can be handled fairly
easily because most standard statistics software
programs compute a heteroskedasticity-robust
covariance matrix.
Usually the sampling probability function, pig , is
unknown and needs to be estimated. Assume a
parametric form pðt; yÞ for pðtÞ is known except for
the unknown y. Let si ¼ IðCi  Tin Þ. Using the
sample, fðZi ; s%i Þ : i ¼ 1; . . . ; Ng where s%i ¼ 1  si ,
# of
we construct a consistent estimator p# ðtÞ ¼ pðt; yÞ
pðtÞ. Then,
#
i ¼ 1; . . . ; N; g ¼ 1; . . . ; G
ð4Þ
p# ig ¼ p# ðT n ; yÞ;
ig

Application of Lemma 4.3 in [15] shows that if pig
in (2) is replaced by p# ig , under the conditions in
which the uniform weak law of large numbers can
be applied, then b#wp consistently estimates b.
Except where censoring is exogenous, one should
adjust the variance matrix in (3) to account for the
ﬁrst stage estimation of censoring probabilities.
The adjusted variance matrix is given in (A7) in
Appendix A.

i¼1

where
# wp ¼
A

N

1

N
X

# 0X
#
X
i i

!

Random eﬀects model

i¼1

# i ¼ Si P1 Xi , y# i ¼ Si P1 yi , and Pi is G  G
X
i
i
diagonal
pﬃﬃﬃﬃﬃﬃ matrix in which the gth diagonal element
is pig where
pig ¼ PðCi  Tign jTi Þ ¼ pðTign Þ

ð2Þ

and pðtÞ ¼ P½Ci  t. Then, b#wp is consistent,
asymptotically normal and its asymptotic robust
variance matrix is estimated by
# 1 B
# wp ¼ A
# # 1
V
wp wp Awp =N
Copyright # 2006 John Wiley & Sons, Ltd.

ð3Þ

Panel data usually provide researchers with a large
number of data points that increase the degrees of
freedom and reduce collinearity among explanatory variables. It also provides a way to resolve or
reduce the magnitude of an econometric problem
that often arises in empirical studies, namely,
omitted variables that are correlated with explanatory variables. One has greater ﬂexibility in
controlling for the eﬀects of unobserved variables
by using information on both the intertemporal
dynamics and the individuality of the entities being
investigated [16].
Health Econ. 15: 513–525 (2006)
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Let us ﬁrst investigate assumptions under which
the random eﬀects estimator is consistent under
exogenous censoring. The model is the unobserved
eﬀects model for any i and all G time periods
yi ¼ X i b þ v i

ð5Þ

where Xi is G  K, b is K  1, and vi is the vector
of composite errors, ai jG þ ui , where ai is the
unobserved heterogeneity and jG is G  1 vector
with all entries equal to 1.
Assumption 2.
(i)
(ii)
(iii)
(iv)

Eðvi jXi Þ ¼ 0;
Eðvi jXi Þ ¼ Eðvi jXi ; Si Þ;
rank EðX0i R0 Si RXi Þ ¼ K;
Eðvi v0i jXi ; Si Þ ¼ X, where X ¼ R1 ðR0 Þ1 . Assuming X is positive deﬁnite, R can be
taken as the unique G  G lower triangular,
nonsingular matrix with positive diagonal
elements.

As with the POLS, a random eﬀect analysis,
puts ai into the error term and imposes more
restrictive assumptions. The random eﬀect approach exploits the serial correlation in the
composite error in a generalized least squares
(GLS) framework. In order to ensure feasible GLS
is consistent under exogenous censoring, we need
assumption 2(i)–(iv).
Typically, we would assume that X has the
standard random eﬀects form. This standard
random eﬀect form is X ¼ s2u IG þ s2a jG j0G , where
Eðu2ig Þ ¼ s2u , Eða2i Þ ¼ s2a , IG is G  G identity
matrix and jG j0G is the G  G matrix with unity in
every element. There is a simple analytical form
for R when X has the random eﬀect form. To see
this, deﬁne zg ¼ f½ðgs2a þ s2u Þ=½ðg þ 1Þs2a s2u þ s4u g1=2
for g ¼ 1; 2; . . . ; G and z0 ¼ ½1=ðs2a þ s2u Þ1=2 . Then
R can be written as:
0

zG1

B
2
B  sa zG1
B ðG1Þs2a þs2u
B
B
..
B
.
B
@

0



zG2

0

s2 z

a G2
ðG2Þs
2 þs2
a

..
.

u

..

.

1
C
C
C
C
C
C
C
A
z0

However, this standard random eﬀect form
assumption on X is not necessary for the following
theoretical development. We can transform
Copyright # 2006 John Wiley & Sons, Ltd.

Equation (5) to
yni ¼ Xni b þ vni
where yni ¼ Ryi ; Xni ¼ RXi and vni ¼ Rvi .
The reason why we choose R as a lower
triangular matrix is due to the attrition problem.
Note that ðxig ; yig Þ is observed if and only if
ðxig ; yig Þ and ðxis ; yis Þ are observed, s5g. Therefore
because R is lower triangular, ðxnig ; ynig Þ is observed
if and only if ðxig ; yig Þ is observed. Then Si Xni is
observed. This would not be true if we do not
choose R lower triangular, or if we have other
patterns of missing data.
Using this set-up, we obtain the unweighted
GLS estimator of b
!1
!
N
N
X
X
0
0
1
n
n
1
n
n
X Si X
N
X Si y ð6Þ
b#ur ¼ N
i

i

i

i¼1

i

i¼1

Obtaining GLS requires knowing X up to scale. In
feasible GLS (FGLS) estimation, we replace the
unknown matrix X with a consistent estimator and
get asymptotic properties that are identical to
those of the GLS estimator. For example, under
the standard random eﬀects form assumption, we
can replace s2a and s2u with their consistent
estimators, respectively,
N X
G1 X
G
X
1
u* ig u* is
ð7Þ
s# 2a ¼
½NGðG  1Þ=2  K i¼1 g¼1 s¼gþ1

s# 2u

¼

N X
G
X
1
u* 2
½NG  K i¼1 g¼1 ig

!
 s# 2a

ð8Þ

where u* ig is the estimated ith POLS residual at the
gth interval.
This estimator is feasible and the consistency of
b#ur follows under assumption 2(i)–(iv). Explicitly,
by the usual law of large numbers argument, and
by using Equation (6)
p lim b#ur ¼ ½EðX0i R0 Si RXi Þ1 EðX0i R0 Si Ryi Þ ¼ b
To obtain the asymptotic variance of b#ur , let
Aur ¼ EðX0i R0 Si RXi Þ, and write
N
pﬃﬃﬃﬃ
X
N ðb#ur  bÞ ¼ A1
N 1=2
X0i R0 Si Rvi
ur

!
þ op ð1Þ ð9Þ

i¼1
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The asymptotic
variance of the bracketed term in
0
(9) is EðXni Si Rvi v0i R0 Si Xni Þ. Under assumption 2(iv)
this reduces to Aur . This shows that the asymptotic
variance of the LHS of Equation (9) can be
estimated by
!1
N
X
1
0
0
# ur ¼ N
X R Si RXi
ð10Þ
V

By the usual law of large numbers argument
p lim b#wr ¼ ½EðX0i R0 S* i RXi Þ1 EðX0i R0 S* i Ryi Þ
But the usual iterated expectations argument gives
EðX0i R0 S* i RXi Þ ¼ E½X0i R0 EðS* i jXi ; yi ÞRXi 
¼ E½X0i R0 RXi 
¼ E½X0i X1 Xi 

i

i¼1

assuming that we know R. Otherwise, assuming
the standard form of X and the derived form R, (7)
and (8) produce an estimate of R.
Correlation between the survival times and
medical costs would violate exogenous censoring
assumption 2(ii), making b#ur inconsistent. Inverse
probabilitypweighted
estimation produces consisﬃﬃﬃﬃ
tent and
N asymptotically normal estimators
even under violation of the assumption 2(ii) if the
following assumptions hold.
Assumption 20 .

Essentially
the
same
argument
gives
EðX0i R0 S* i Ryi Þ ¼ E½X0i X1 yi . Therefore, under the
assumption 2(i) and obvious rank condition
assumption rank EðX0i X1 Xi Þ ¼ K
p lim b#wr ¼ E½X0i X1 Xi 1 E½X0i X1 yi  ¼ b
To obtain the asymptotic variance of b# wr let
Awr ¼ EðX0i X1 Xi Þ, and write
!
N
pﬃﬃﬃﬃ
X
1
1
0 0*
#
Xi R Si Rvi þ op ð1Þ
N ðbwr  bÞ ¼ Awr N
i¼1

Then

0

(i) EðXni 0 vni Þ ¼ 0;
(ii) EðXni Xni ) has rank K;
(iii) xig and yig are ignorable in the selection
equation, that is,
Pðsig ¼ 1jXi ; yi ; Ti Þ ¼ Pðsig ¼ 1jTi Þ
¼ PðCi  Tign jTi Þ
As in the case of POLS, another advantage of
weighting the observations, other than solving the
censoring problem is that we derive consistency
with the weaker assumption 20 (i) rather than
assumption 2(i). Assumption 20 (ii) is the appropriate rank condition. In terms of conditioning set,
assumption 20 (iii) is much stronger than the one
presented under POLS section. Write S* i ¼ Si P1
i .
Using this set-up, IPW RE estimator is
!1
!
N
N
X
X
0
0
1
n
n
1
n
n
X S* i X
N
X S* i y
b#wr ¼ N

A var½

pﬃﬃﬃﬃ
1
N ðb#wr  bÞ ¼ A1
wr Bwr Awr

where Bwr ¼ EðX0i R0 S* i Rvi v0i R0 S* i RXi Þ. Both Awr and
Bwr can be consistently estimated, and there are no
simpliﬁcations even under all the assumptions of
the random eﬀects model in the population. The
estimated asymptotic variance of IPW RE estimator is, therefore,
!1
N
X
1
0 0*
#
X R Si RXi
Vwr ¼ N
i

i¼1



N

1

N
X

* i R#vi v# 0 R0 S
* i RXi
X0i R0 S
i

i¼1



N

1

N
X

X0i R0 S* i RXi

!

!1
ð11Þ

i¼1

where v# i ¼ yni  Xni b#wr .
As in the case of POLS, except when the
# wr is unadjusted, becensoring is exogeneous, V
i
i
i
i
at
the ﬁrst stage has not
cause
the
estimation
of
P
i
i¼1
i¼1
been accounted for. The adjusted variance matrix
We can estimate R by using IPW POLS residuals can be obtained by applying the results from
in Equations (7) and (8), assuming the selection Appendix A. Usually, the adjustment for estimaprobabilities in Pi are known or can be estimated. tion at the ﬁrst step has little eﬀect on the
This makes the estimator feasible. To derive the asymptotic standard errors.
As mentioned previously, our cost vector yi may
consistency of b# wr write
include
zero components. With RE model, the
!1
!
N
N
linear transformation Si R is applied to the vector
X
X
b#wr ¼ N 1
X0i R0 S* i RXi
N 1
X0i R0 S* i Ryi
yi in the unweighted case, and Si P1
i R is used in
i¼1
i¼1
the weighted case. In both situations, it is very

Copyright # 2006 John Wiley & Sons, Ltd.
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unlikely in practice to have many zeros values in
the ﬁnal analysis vector Si Ryi or Si P1
i Ryi . The
asymptotic theory of the estimators b#ur and b#wr is
still valid. However, this does not say anything
about how good the model ﬁt would be.
The cost of treating patients who have died
usually accelerate as the patient gets closer to
death. Since our model allows for estimating cost
in a period among those who died relative to those
survived, we only need to add a time by death
status interaction term. Costs of those who die in a
period can be compared with costs of those who
survived that period. These same groups can also
be compared for the period before death. To
model this we need: (i) intercept, (ii) period
indicator, (iii) interaction of period and death
indicators.

Weighted or unweighted estimator?

weighted and unweighted POLS, choose h#w , h#u as
# V
#w V
# u , where V
#w
b#wp , b#up , respectively. V
# u by (13) under the
is given by (3) and V
homoskedasticity assumption.
For the RE model, h#w and h#u are b#wr and b#ur ,
# u by (10). In
# w is given by (11) and V
respectively. V
many cases we may want to use a Hausman test
when the homoskedasticity assumption is violated.
# for
This requires a robust form that replaces V
POLS estimation by
!
N X
G
X
1
1
1
0
#
# 1 Þ0 =N
# 1 j  A
#
e# ig e# ðA
ðA j A Þ N
wp

up

ig

wp

up

i¼1 g¼1

where ð:j:Þ denotes the augmented matrix obtained
# ig u# ig x0ig ;
by appending two matrices and e# ig ¼ ðw
0 0
sig u* ig xig Þ . u# ig and u* ig are the residuals after
weighted and unweighted POLS estimation. For
# by
RE estimation, we replace V
!
N
X
# 1 Þ N 1
# 1 Þ0 =N ð14Þ
# 1 j A
# 1 j A
*ei *e0 ðA
ðA
wr

ur

i

wr

ur

i¼1

It has been shown that the unweighted estimator is
no less eﬃcient than the weighted estimator under
homoskedasticity and exogenous censoring [7].
For a linear regression model, the Gauss–Markov
Theorem for independent observations implies
that the OLS estimator is the best linear unbiased
estimator. It is better than any other weighted
estimator, which is linear and unbiased.
Because the unweighted estimator is inconsistent
when the censoring scheme is not exogenous and
the weighted estimator is consistent with or
without exogenous censoring, we can apply a
Hausman test [13] to determine exogeneity of
censoring. The traditional form of Hausman
statistics can be used under the homoskedasticity
assumption. We can state this assumption for the
POLS estimator as follows:
* i Þ ¼ s2 EðX
* iÞ
* 0X
* 0 u* i u* 0 X
ð12Þ
EðX
i

0

i

i

When Equation (12) holds, estimation of the
unweighted POLS variance estimator is simpliﬁed
further
# 1
# up ¼ s# 2 A
ð13Þ
V
up

provided we have a consistent estimator s# 2 of s20 .
In general form, the Hausman test statistic can
be stated as
# 1 ðh#w  hu Þ
H ¼ ðh#w  h#u Þ0 V
The distribution of H under the null hypothesis
is chi-square with K degrees of freedom. For
Copyright # 2006 John Wiley & Sons, Ltd.

* i RXi v# i ; X0 R0 Si RXi *vi Þ0 , and v# i ; *vi
where *ei ¼ ðX0i R0 S
i
are the residuals after weighted and unweighted
RE estimation.
If the Hausman test indicates rejection, then the
assumption of exogenous censoring is violated,
and the unweighted estimators are inconsistent.
A failure to reject means the coeﬃcients from
unweighted and weighted estimators are not
systematically diﬀerent. The typical response is to
conclude that the exogeneity assumption holds
and therefore, we should use OLS estimates.
Unfortunately due to the low power of the
Hausman test we might commit a Type II error.
Therefore, it is recommended that the results from
both estimations be presented.

The lung cancer study
Data
The data set is derived from a broader study of
health care cost, utilization and physical health
function in a cohort of newly diagnosed elderly
lung cancer patients recruited from several Michigan oncology clinics during 1994 through 1997.
For our application, we use data from 201 (out of
223) Medicare beneﬁciaries age 65 or older who
agreed to participate in this study. We excluded 22
Health Econ. 15: 513–525 (2006)
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patients because their demographic data was
missing. Detailed cost data were obtained from
Medicare claim ﬁles for each patient for a 2-year
period following diagnosis. Payments by Medicare
were used as a proxy for direct Medicare costs
(as opposed to billed charges).
Patient demographic data were obtained
through interviews. Physical function 3 months
prior to diagnosis was measured by the short form
SF-36. The physical function subscale of the SF-36
[17] is a 10 item measure of patients ability to

perform a series of ordered activities including
lifting, bending, stooping, and carrying packages
of a given weight, walking diﬀerent distances, and
climbing stairs and performing self care activities
such as dressing and bathing oneself. The scale is a
weighted sum score with 100 representing high
level of functioning and lower scores indicating
persons who are less able to perform physical
activities. Comorbid conditions were assessed
using questions from the Aging and Health in
America Survey (1996), which documents 15

Table 1. Summary statistics from the lung cancer study
Variable
Total cost
Age
Physical functioning
Symptoms

Mean ðN ¼ 4335Þ

Variable description
Total
medicare payments
P
(Inpatient, Outpatient, Provider)
Patient’s age within two weeks of
initiating either radiation or chemotherapy
Three months prior to diagnosis
using the subscale from the SF-36
A count of all symptoms

Pays all

¼ 1 if patient’s comorbid
conditions are three or more
¼ 1 if patient’s disease
stage is regional, distant or invasive
¼ 1 if patient’s race is white
stage is regional, distant or invasive
¼ 1 if patient’s gender is male
stage is regional, distant or invasive
¼ 1 if insurance coverage pays all expenses

Pays more

¼ 1 if insurance coverage requires minor expenses

Pays little

¼ 1 if insurance coverage requires many expenses

Pays none

¼ 1 if many services are not covered

No treatment

¼ 1 if patient received
no treatment
¼ 1 if patient received
surgery only
¼ 1 if patient received
surgery and chemotherapy
¼ 1 if patient received
surgery and radiation
¼ 1 if patient received
surgery, chemotherapy and radiation
¼ 1 if patient received
chemotherapy and radiation
¼ 1 if patient received
chemotherapy only
¼ 1 if patient received
radiation only

Comorbidity
Late stage
White
Male

Surgery
Surgery & Chemo
Surgery & Radiation
Surgery & Chemo & Radiation
Chemo & Radiation
Chemotherapy
Radiation

$2620
($7175)
71.97
(4.85)
72.10
(27.30)
10.87
(4.99)
0.65
(0.48)
0.64
(0.48)
0.93
(0.27)
0.59
(0.49)
0.40
(0.49)
0.48
(0.50)
0.09
(0.29)
0.03
(0.17)
0.8104
(0.3920)
0.01407
(0.1178)
0.0005
(0.2147)
0.0002
(0.0151)
0.0018
(0.0429)
0.0209
(0.1434)
0.0911
(0.2878)
0.0609
(0.2392)

Standard deviations are in parentheses.
Copyright # 2006 John Wiley & Sons, Ltd.
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Figure 1. The distribution of average monthly cost values for
uncensored cases

diseases and health problems other than lung
cancer. Disease stage was determined by the
Tumor Nodes and Metastasis (TNM) staging
system of the American Joint Committee on
Cancer (AJCC) using the pathological data
obtained from audit of patients’ medical records.
Table 1 shows the summary statistics for each
variable as well as short description of the variables.
A patient’s medical cost was regarded as
censored if the patient was alive at the end of
1997 and if follow up was less than two years.
Because censoring is solely due to the limit of study
duration, it is reasonable to assume that censoring
is independent of all other random variables.
Figure 1 shows the distribution of average
monthly costs for uncensored cases. Expenditure
shows a spike in the ﬁrst month after diagnosis due
to surgery. Interventions such as surgery and
radiation incur large costs within the ﬁrst few
months of following diagnosis, whereas chemotherapy, which is less costly, may be administered over a much longer time.

Regression analysis
Two analyses were performed to examine how
patient- and treatment-related variables explain
total medical cost for older persons newly diagnosed with lung cancer. In particular, we are
interested in how various treatment regimens (e.g.
surgery only, chemotherapy, radiation, and combinations of surgery, chemotherapy, and radiation) aﬀected the total cost of lung cancer care.
Total medical cost is the expenditure incurred
from initiation of treatment until death or for a
2-year period, whichever comes ﬁrst. Monthly
Copyright # 2006 John Wiley & Sons, Ltd.
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expenditures were derived for this period. Following Manning and Mullahy [18] the cost estimates
satisﬁed conditions for which an OLS-based model
for log-transformed dependent variable was
appropriate. One of the disadvantages of logtransformed models are zero cost observations.
We did not have zero-cost as long as the individual
was alive. Since we are considering total cost, some
cost would be observed even there is no treatment.
We did have a zero cost issue, if an individual died.
In our sample, however, only 5 patients out of 201
died during the study period. We assumed that
these patients had a cost of $1 per month,
following the month death, so that when we
transformed cost into its natural log, the cost per
month would then be 0. If the percentage of
patients died was higher, we would have used
generalized linear model (GLM) approach suggested by Manning et al. [19]. Table 2 shows the
results of the regression analysis for correlates of
the total cost.
Because the population may have a diﬀerent
distribution in diﬀerent periods we allowed the
intercept to diﬀer across diﬀerent months. These
are the time dependent factors. The ﬁrst month
after diagnosis was the base month and dummy
variables were added for all other months. The
estimated coeﬃcients were all negative and statistically signiﬁcant ðp50:05Þ. (These results are not
shown).
The control variables include time independent
covariates such as gender, race, comorbid conditions, stage of cancer and physical functions and
time dependent covariates such as age and treatment-related variables. We divided treatment into
seven categories: no treatment, radiation only,
chemotherapy only, surgery and radiation, surgery
and chemotherapy, chemotherapy and radiation,
and ﬁnally surgery, chemotherapy and radiations.
The latter was chosen as the reference group.
In our sample, all subjects are enrolled in
Medicare and thus insurance payer is exogenous.
Researchers using data from subjects that have
other forms of insurance (or are uninsured) may
want to include insurance payer as an explanatory
variable.
Disease severity, as measured by cancer stage,
had a statistically signiﬁcant eﬀect under both
IPW RE and IPW POLS models. Regional stage
decreased total cost of care almost 68% according
to IPW POLS and 41% according to IPW RE
compared to in situ or local stage cancer.
On average, expenses for patients who had no
Health Econ. 15: 513–525 (2006)
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Table 2. Estimates of the log transformed total medical cost

Variable
Age
Physical functioning
Symptoms
Comorbidity
Late stage
White
Male
Pays more
Pays little
Pays none
Surgery
Surgery & Chemo
Surgery & Chemo & Radiation
Surgery & Radiation
Chemo & Radiation
Chemotheraphy
Radiation
Constant
Monthly dummies
R-squared

POLS

IPWPOLS

RE

IPWRE

n ¼ 4335

n ¼ 4335

n ¼ 4335

n ¼ 4335

0.0044
(0.0183)
0.0031
(0.0035)
0.0013
(0.0191)
0.2053
(0.1989)
1.1153
(0.2049)nn
0.1955
(0.3812)
0.1843
(0.1915)
0.1746
(0.1993)
0.1817
(0.3717)nn
0.4758
(0.3911)
5.7724
(0.2084)
4.8626
(0.7230)
6.3000
(0.4585)
5.7719
(0.2959)
5.7356
(0.1936)
5.2680
(0.1768)nn
4.8976
(0.1804)nn
5.2925
(1.6023)nn
Yes
0.7179

0.0038
(0.0184)
0.0024
(0.0035)
0.0027
(0.0193)
0.2293
(0.1996)
1.1887
(0.2086)nn
0.2289
(0.3752)
0.1846
(0.1946)
0.1783
(0.2004)
0.1492
(0.3863)nn
0.5136
(0.4073)
5.7976
(0.2098)
4.8787
(0.7176)
6.3184
(0.4523)
5.7822
(0.2989)
5.7774
(0.1937)
5.3257
(0.1792)nn
4.9337
(0.1807)nn
5.2426
(1.5999)nn
Yes
0.7305

0.033
(0.01911)
0.0019
(0.0039)
0.0004
(0.0205)
0.0204
(0.2054)
1.0626
(0.2040)nn
0.0306
(0.4511)
0.1691
(0.1944)
0.1243
(0.3651)
0.2696
(0.3651)nn
0.5501
(0.3889)
5.3409
(0.2678)
5.0051
(0.5007)
3.8124
(0.2067)
5.7458
(0.3572)
5.4732
(0.2273)
4.7609
(0.1787)
4.6567
(0.1879)n
5.6180
(1.7307)nn
Yes
0.7512

0.05342
(0.02196)
0.0065
(0.0042)
0.006
(0.0228)
0.3271
(0.2205)
1.1212
(0.2301)nn
0.1614
(0.4803)
0.1299
(0.2144)
0.0471
(0.2277)
0.1446
(0.4358)nn
0.9925
(0.5359)
5.4178
(0.2691)
5.1912
(0.4546)
3.8299
(0.20695)
5.8515
(0.3705)
5.5766
(0.2299)
4.8458
(0.1832)
4.7324
(0.1877)n
5.7946
(1.9492)nn
Yes
0.7564

Robust standard errors in parentheses n signiﬁcant at 5%;

nn

signiﬁcant at 1%.

treatment were almost 99% less than for the
patients who had surgery chemotherapy and
radiation according to the IPW POLS and 4.46
times greater according to IPW RE models. A
person who received radiation only had decreased
the total medical cost relative to the average cost
for persons with surgery plus adjuvant therapies.
The estimates with respect to IPW POLS and IPW
RE are 72 and 49%.
The Hausman test comparing the POLS
and IPW POLS, and RE and IPW RE models,
Copyright # 2006 John Wiley & Sons, Ltd.

suggest that the exogenous censoring assumption
is not violated. Thus, coeﬃcients from weighted
and unweighted estimations are both consistent.

Conclusion
Measurement of treatment cost is especially
important in the evaluation of medical interventions, in the analysis of clinical trials, and in social
Health Econ. 15: 513–525 (2006)
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experiments. However, because cost records are
incomplete, it is diﬃcult to estimate cost accurately. Current statistical methods that would be
applicable to administrative data, which is often
censored, are under-developed.
One advantage of cost data is that they often ﬁt
naturally into a panel data format. This paper
estimates medical cost per patient as a linear
function of time varying covariates over a time
interval ½0; L following diagnosis. This interval is
divided into G periods, so a panel structure arises.
Censoring (in some periods) occurs when, for a
given patient, the follow-up time is smaller than L
and smaller than the survival time of the patient.
The IPW least squares method was applied to
longitudinal data to illustrate how possible censoring bias can be removed. The main motivation
for developing the method is to handle a large
number of continuous and discrete covariates.
We analyzed POLS and RE models and
examined their statistical properties under censoring. Without exogenous censoring, the usual
POLS and RE estimators are inconsistent. Generally, censoring is not exogenous because perperiod medical cost may not be independent of
survival time and the later is not independent of
whether or not censoring occurs. To correct for
censoring bias, we propose using IPW estimators,
either in a pooled OLS or in a random eﬀects
framework.
IPW estimators are consistent and
pﬃﬃﬃﬃ
N asymptotically normal. We also derived these
estimators’ ﬁrst stage adjusted variance matrix.
Since unweighted POLS and RE estimators are
consistent under exogenous censoring and more
eﬃcient under the homoskedasticity assumption,
the Hausman test can be used to compare the
systematic diﬀerences in coeﬃcients between
weighted and unweighted estimators. This test
can be use to ascertain whether the exogenous
censoring assumption is violated and whether the
censoring bias creates statistically meaningful
diﬀerences in the coeﬃcients. We also derived
and applied robust forms of the Hausman test in
case the homoskedasticity assumption is violated.
Although it does not demonstrate the full power
of the IPW least squares method, the lung cancer
study demonstrated our proposed regression
methods and test statistics. We fail to reject the
hypothesis that the exogenous censoring assumption is violated. In order to see that this assumption was not violated in the lung cancer example,
we needed to apply IPW estimation. Thus while
the censoring bias created by applying POLS or
Copyright # 2006 John Wiley & Sons, Ltd.

RE on complete observations does not produce
statistically diﬀerent results than IPW POLS and
IPE RE produce, though the latter two do correct
for possible censoring bias.
One of the problems with medical cost data is
fraction of zeros. This is especially dominant when
we analyze subcategory costs such as inpatient
costs. In order to deal with skewness generalized
linear models (GLM) are proposed by several
authors [18–20]. Especially with cost-per-individual per month analysis, those without the disease
will have even higher fraction of zeroes than
they do for annual data. Further, the subperiod
data on positive expenditures will be even more
skewed than is the case for annual data. Here, we
are faced with the robustness-eﬃciency trade-oﬀ,
which is very common in econometrics. Our
analysis is probably more eﬃcient with monthly
data, but less robust than an analysis that uses just
annual data. Although we focus on log-transformed OLS on modeling medical cost data, the
present framework can be adapted to GLM
models to deal with both zeroes and skewness
assuming that the correct link function is known
or is estimable.
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Appendix A: Derivation of IPW POLS
Variance Matrix adjusted to ¢rst stage
estimation of censoring probabilities
#
Let b# be IPW POLS estimator
!1
N X
G s x x0
X
ig ig ig
##
1
bwp ¼ N
p# ig
i¼1 g¼1
!
N X
G
X
sig xig yig
1
 N
p# ig
i¼1 g¼1

ðA1Þ
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where p# ig is deﬁned in Equation (4) in the main
#
text. It is convenient to express p# ig as pðTign ; yÞ,
where y# is the vector of estimated parameters that
appear in the ﬁrst stage estimation. As mentioned
#
in the text, consistency of b# wp be easily read oﬀ
from (A1) by using Lemma 4.3 in Newey and
McFadden [15] under usual assumption. In the
application here, we need to obtain the asymptotic
pﬃﬃﬃ
variance of nðb## wp  bwp Þ when pig ’s are estimated
in the preliminary stage.
By substituting for yig , (A1) can be re-written as
!1
0
N X
G
X
pﬃﬃﬃ #
s
x
x
ig
ig
ig
nðb# wp bwp Þ¼ N 1
n
#
i¼1 g¼1 pðTig ; yÞ
!
N X
G
X
sig xig uig
1=2
 N
ðA2Þ
#
pðT n ; yÞ
i¼1 g¼1

ig

Applying the uniform law of large numbers
(Lemma 4.3 of Newey and McFadden [15]) shows
that the ﬁrst term on the right-hand side of (A2)
converges to
!
!
G
G
X
X
sig xig x0ig
0
xig xig ¼ Aw ðA3Þ
¼E
E
pðTign ; y0 Þ
g¼1
g¼1
where y0 is the true parameter. Standard maximum likelihood estimation is used to estimate
# The part of the likelihood of ðZi ; si Þ
y0 by y.
that is relevant for estimation of y has the
form fpðZi ; yÞgsi fgðZi ; yÞg1si fpðtG ; yÞg½T ^ C > tg 
where gðt; yÞ is a density for Ci . We need to assume
that pðtG ; yÞ > 0 and that y ! gð:; yÞ to fulﬁll all
regularity conditions needed for maximum likelihood estimation of y.
Note that zi 2 ðtg1 ; tg  and si ¼ 1 is equivalent
to ½Ci  Tign ½tg1  Tign 5tg  ¼ sig Ig ðTign Þ, whereas
zi 2 ðtg1 ; tg  and si ¼ 0 is equivalent to
½tg1  Ci 5Tign  ¼ ð1  sig ÞIg ðCi Þ, where Ig ðtÞ ¼
½tg1  t5tg : To include the interval t  tG ,
deﬁne the indicator IGþ1 ðtÞ ¼ ½t  tG . Then the
derivative with respect to y of the aforementioned
log-likelihood can be written
(
G
X
ry pðTign ; yÞ
ry gðCi ; yÞ
þð1sig ÞIg ðCi Þ
sig Ig ðTign Þ
n
gðCi ; yÞ
pðTig ; yÞ
i¼1

ry pðL; yÞ
þð1=GÞIGþ1 ðTi ^ Ci Þ
pðL; yÞ
G
X
¼
dig ðyÞ
i¼1
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P PG
The estimator y# is a solution N
i¼1
i¼1 dig ðyÞ ¼ 0.
#
Consistency of y follows from the standard
regularity conditions on the function y ! gð:; yÞ
for maximum likelihood estimation of y.
Let y0 be the true parameter. Note that dig ðy0 Þ
is a q  1 vector. Using a Taylor expansion of
PN PG
#
i¼1
i¼1 dig ðyÞ ¼ 0 at y0 , one can show
pﬃﬃﬃ
nðy#  y0 Þ
!
N X
N
pﬃﬃﬃﬃ X
1
N
dig ðy0 Þ þ op ð1Þ ðA4Þ
¼ J ðy0 Þ
i¼1 g¼1

PG

P
0
where Jðy0 Þ ¼ Eð g¼1 dig ðy0 ÞÞð G
g¼1 dig ðy0 ÞÞ is a
q  q matrix.
By using the standard asymptotic representation
of a maximum likelihood estimator based on the
information matrix equality and (A4), we can
write the second term on the right-hand side of
(A2) to get
N 1=2

N X
G
X
sig xig u0ig
#
pðT n ; yÞ
i¼1 g¼1

¼ N 1=2

N
X

ig

fki  Dðy0 ÞJ 1 ðy0 Þdi ðy0 ÞjG g þ op ð1Þ

ðA5Þ

i¼1

where di ðy0 Þ ¼ ½di1 ðy0 Þ; . . . ; diG ðy0 Þ is a q  G
matrix, jG is a G  1 vector of 1’s, and Dðy0 Þ ¼
P PG sig xig uig
0
n
Eð N
* 2 ðry pðTig ; y0 ÞÞ Þ is a K  q
i¼1
g¼1 ðpðT n ;yÞÞ
ig
P
sig xig u0ig
matrix, and ki ¼ G
g¼1 pðT n ;y0 Þ is a K  1 vector.
ig

Combining the terms, (A2) can be re-written as
!
N
X
pﬃﬃﬃ #
ei þ op ð1Þ ðA6Þ
nðb# wp b Þ ¼ A1 N 1=2
wp

w

i¼1

where ei ¼ ðki  Dðy0 ÞJ 1 ðy0 Þdi ðy0 ÞjG Þ. A direct
calculation of the variance matrix of the rightpﬃﬃﬃ #
hand side of (A6) shows that
nðb#  bw Þ has
1
where
asymptotic variance Vwa ¼ Aw Fw A1
w
Fw ¼ Eðki k0i Þ  Dðy0 ÞJ 1 ðy0 ÞD0 ðy0 Þ.
Under exogenous censoring (see assumption 1)
we get Dðy0 Þ ¼ 0 and so the asymptotic variance
1
0
which is the
reduces to Vwa ¼ A1
w Eðki ki ÞAw
#
asymptotic variance matrix of bwp in the main text
(see (3)). This is the variance if the censoring
probabilities were known. In general, the diﬀerence Vwa  Vwu is negative deﬁnite which makes
the asymptotic variance after ﬁrst stage estimation
no larger than that if the ﬁrst stage was ignored.
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